Skip to main content
PMC home page
International Journal of Methods in Psychiatric Research logoLink to International Journal of Methods in Psychiatric Research
. 2008 Jan 10;16(4):186–201. doi: 10.1002/mpr.229

Methodological approaches in the assessment of interferon‐alfa‐induced depression in patients with chronic hepatitis C – a critical review

Arne Schäfer 1,✉, Hans‐Ulrich Wittchen 2, Jochen Seufert 3, Michael R Kraus 1
PMCID: PMC6878515  PMID: 18188838

Abstract

In recent years, research on interferon (IFN)‐induced depressive symptoms in antivirally treated patients suffering from chronic hepatitis C (CHC) has considerably intensified. Profound scientific knowledge of this complication is of great relevance with regard to adherence, compliance, and premature therapy discontinuation.

Presently, there is considerable variability of both, the frequency and extent of IFN‐induced depression reported in different cohorts of patients.

The aim of the presented study was to systematically review recent literature of research within this field; and particularly (1) to identify to what extent methodological bias contributed to inconsistent results in different studies, (2) to critically appraise methods and results of studies published so far, and (3) to suggest directions for future work, especially with respect to alternative and improved methodological approaches.

The results of this critical review suggest that the variability of findings seem to be largely due to different study populations, treatment regimens, methodological approaches, and sometimes arbitrary or at least poorly defined choice of screening instruments for depression, particularly criteria for clinically relevant depression (cut‐off criteria).

Study designs and methodological approaches to investigate IFN‐alfa‐induced depression in patients with CHC have been incoherent. Future research in this field needs agreement on the use of standardized assessment of IFN‐induced depression in CHC. Furthermore, objective criteria and guidelines for the treatment of IFN‐induced depression in these patients are needed in clinical practice. Copyright © 2008 John Wiley & Sons, Ltd.

Keywords: interferon, depression, hepatitis C, methodological approaches, psychometric instruments

Full Text

The Full Text of this article is available as a PDF (299.9 KB).

REFERENCES

  1. Angelino AF, Treisman GJ. Evidence‐informed assessment and treatment of depression in HCV and interferon‐treated patients. Int Rev Psychiatry 2005; 17: 471–6. [DOI] [PubMed] [Google Scholar]
  2. American Psychiatric Association (APA) . Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV‐TR. Washington, DC: APA, 2000. [Google Scholar]
  3. Asnis GM, De La Garza R. Interferon‐induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 808–18. [DOI] [PubMed] [Google Scholar]
  4. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52: 81–5. [DOI] [PubMed] [Google Scholar]
  5. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71. [DOI] [PubMed] [Google Scholar]
  6. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health‐related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704–8. [DOI] [PubMed] [Google Scholar]
  7. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon‐alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237–41. [DOI] [PubMed] [Google Scholar]
  8. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370. [DOI] [PubMed] [Google Scholar]
  9. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Neurobehavioral effects of interferon‐alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643–52. [DOI] [PubMed] [Google Scholar]
  10. Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa‐induced depression in patients with chronic hepatitis C. Hepatology 2002; 35: 978–9. [DOI] [PubMed] [Google Scholar]
  11. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes‐Mainard J, Henry C. Mood alterations during interferon‐alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005; 66: 1050–7. [DOI] [PubMed] [Google Scholar]
  12. Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400–6. [DOI] [PubMed] [Google Scholar]
  13. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM. Depression, anemia and health‐related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491–8. [DOI] [PubMed] [Google Scholar]
  14. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–6. [DOI] [PubMed] [Google Scholar]
  15. Davis GL, Esteban‐Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa‐2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–9. [DOI] [PubMed] [Google Scholar]
  16. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997; 26: 794–7. [DOI] [PubMed] [Google Scholar]
  17. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon‐alpha‐2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104–12. [DOI] [PubMed] [Google Scholar]
  18. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160: 172–4. [DOI] [PubMed] [Google Scholar]
  19. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47. [DOI] [PubMed] [Google Scholar]
  20. Forton DM, Taylor‐Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18: 333–8. [DOI] [PubMed] [Google Scholar]
  21. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–12. [DOI] [PubMed] [Google Scholar]
  22. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–91. [DOI] [PubMed] [Google Scholar]
  23. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237–44. [DOI] [PubMed] [Google Scholar]
  24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr , Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82. [DOI] [PubMed] [Google Scholar]
  25. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garre JB. Psychiatric side effects of interferon‐beta in multiple sclerosis. Eur Psychiatry 2005; 21: 186–93. [DOI] [PubMed] [Google Scholar]
  26. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431–8. [DOI] [PubMed] [Google Scholar]
  27. Hadziyannis SJ, Sette H, Jr , Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr , Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, LIn A, Ackrill AM. Peginterferon‐alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55. [DOI] [PubMed] [Google Scholar]
  28. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open‐label treatment of interferon‐induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942–7. [DOI] [PubMed] [Google Scholar]
  29. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat 2005; 12: 223–35. [DOI] [PubMed] [Google Scholar]
  30. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon‐alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34–8. [DOI] [PubMed] [Google Scholar]
  31. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon‐alpha treatment of chronic hepatitis C on health‐related quality of life. Dig Dis Sci 1997; 42: 2482–6. [DOI] [PubMed] [Google Scholar]
  32. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa‐interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241–3. [DOI] [PubMed] [Google Scholar]
  33. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high‐dose interferon alfa‐2b in patients with high‐risk melanoma. Cancer J 2000; 6: 139–45. [PubMed] [Google Scholar]
  34. Kraus MR, Schäfer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 377–84. [DOI] [PubMed] [Google Scholar]
  35. Kraus MR, Schäfer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001; 345: 375–6. [PubMed] [Google Scholar]
  36. Kraus MR, Schäfer A, Al‐Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha retherapy in patients with chronic hepatitis C and a history of interferon‐induced depression. J Viral Hepat 2005a; 12: 96–100. [DOI] [PubMed] [Google Scholar]
  37. Kraus MR, Schäfer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa‐2b as compared to conventional interferon alfa‐2b in patients with chronic hepatitis C. World J Gastroenterol 2005b; 11: 1769–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon‐alpha‐induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091–9. [DOI] [PubMed] [Google Scholar]
  39. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa‐2b therapy. J Clin Psychiatry 2003; 64: 708–14. [DOI] [PubMed] [Google Scholar]
  40. Loftis JM, Hauser P. The phenomenology and treatment of interferon‐induced depression. J Affect Disord 2004; 82: 175–90. [DOI] [PubMed] [Google Scholar]
  41. Loftis JM, Wall JM, Linardatos E, Benvenga S, Hauser P. A quantitative assessment of depression and thyroid dysfunction secondary to interferon‐alpha therapy in patients with hepatitis C. J Endocrinol Invest 2004; 27: RC16–20. [DOI] [PubMed] [Google Scholar]
  42. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha‐induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93–7. [DOI] [PubMed] [Google Scholar]
  43. Malek‐Ahmadi P. Mood disorders associated with interferon treatment: theoretical and practical considerations. Ann Pharmacother 2001; 35: 489–95. [DOI] [PubMed] [Google Scholar]
  44. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65. [DOI] [PubMed] [Google Scholar]
  45. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92. [DOI] [PubMed] [Google Scholar]
  46. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120. [DOI] [PubMed] [Google Scholar]
  47. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15: 300–3. [DOI] [PubMed] [Google Scholar]
  48. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high‐dose interferon alfa. N Engl J Med 2001; 344: 961–6. [DOI] [PubMed] [Google Scholar]
  49. Nickel T, Sonntag A, Backmund M, Pollmacher T. Depression during therapy with interferon alpha – how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: 102–4. [DOI] [PubMed] [Google Scholar]
  50. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon‐alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131–2. [DOI] [PubMed] [Google Scholar]
  51. Price S, Goyette J. Role of the psychiatrist in the care of patients with hepatitis C and HIV/AIDS. Psychiatr Q 2003; 74: 261–76. [DOI] [PubMed] [Google Scholar]
  52. Radloff LS. The CES‐D scale: a self‐report depression scale for research in the general population. Appl Psychol Measure 1977; 385–401. [Google Scholar]
  53. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon‐alpha: recognition and management. CNS Drugs 2005a; 19: 105–123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon‐alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005b; 66: 41–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Peginterferon alpha‐2a (40kD) [Pegasys] improves HR‐QOL outcomes compared with unmodified interferon alpha‐2a [Roferon‐A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341–9. [DOI] [PubMed] [Google Scholar]
  56. Reichenberg A, Gorman JM, Dieterich DT. Interferon‐induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. Aids 2005; 19(Suppl. 3): S174–8. [DOI] [PubMed] [Google Scholar]
  57. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long‐term interferon alfa therapy. Arch Intern Med 1987; 147: 1577–80. [PubMed] [Google Scholar]
  58. Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre JB, Cales P. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol Clin Biol 1998; 22: 353–7. [PubMed] [Google Scholar]
  59. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711–9. [DOI] [PubMed] [Google Scholar]
  60. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, Redaelli A, Roffi L, Mancia G. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12: 505–9. [DOI] [PubMed] [Google Scholar]
  61. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P, Roffi L. Interferon‐induced depression: prevalence and management. Dig Liver Dis 2005; 37: 102–7. [DOI] [PubMed] [Google Scholar]
  62. Schäfer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443–51. [DOI] [PubMed] [Google Scholar]
  63. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–67. [DOI] [PubMed] [Google Scholar]
  64. Strite D, Valentine AD, Meyers CA. Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9: 273–6. [DOI] [PubMed] [Google Scholar]
  65. Trask PC. Assessment of depression in cancer patients. J Natl Cancer Inst Monogr 2004; 80–92. [DOI] [PubMed] [Google Scholar]
  66. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13: 526–36. [DOI] [PubMed] [Google Scholar]
  67. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 2005; 7: 391–5. [DOI] [PubMed] [Google Scholar]
  68. Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN‐alpha‐induced cognitive‐depressive changes. Psychol Med 2005; 35: 433–41. [DOI] [PubMed] [Google Scholar]
  69. Zdilar D, Franco‐Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207–11. [DOI] [PubMed] [Google Scholar]
  70. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70. [DOI] [PubMed] [Google Scholar]
  71. Zung WW. Depression in the normal aged. Psychosomatics 1967a; 8: 287–292. [DOI] [PubMed] [Google Scholar]
  72. Zung WW. Factors influencing the self‐rating depression scale. Arch Gen Psychiatry 1967b; 16: 543–7. [DOI] [PubMed] [Google Scholar]
  73. Zung WW, Richards CB, Short MJ. Self‐rating depression scale in an outpatient clinic. Further validation of the SDS. Arch Gen Psychiatry 1965; 13: 508–15. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Methods in Psychiatric Research are provided here courtesy of Wiley

RESOURCES